Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801 Haddonfield NJ, September 24, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that the U.S. Food and Drug [...]
Linnaeus Therapeutics Closes $12 Million Series B Financing Linnaeus Therapeutics, Inc. ("Linnaeus"), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that it has closed a $12 million series B financing. Kairos Ventures, of Beverly Hills, California, [...]
Linnaeus Therapeutics Scientific Cofounder Presents Preclinical Pancreatic Cancer Data at AACR Pancreas Cancer Meeting Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that its scientific cofounder, Todd Ridky, MD, PhD, Assistant Professor [...]
